Dear member,
welcome to the new edition of the membership online letter.
We look forward to transmit up to date news and information quickly on this
way to you.

Your ESOP Membershipservice



On October 24th was established new section on www.esop.eu – Case reports. This first is regarding about paclitaxel and gemcitabine stability and storage. We invite you to learn and analyze it (http://www.esop.eu/casereports.php). The next will be published soon. We would like to invite you to creation a new case reports. It would be great if you could describe an interesting situation from your job. The level of oncology pharmacy in Europe is different, therefore yours knowledge and experience may help others who starts. Please do not hesitate to contact with Lukasz Lapinski (ll@esop.li) if you have any queries or concerns.




We invite you to join the 9th NZW-Europe
– European Conference for Oncology Pharmacy (ECOP) meeting in Hamburg.
The 9th European Conference of Oncology Pharmacy will be held between January 28th to 29th 2011 in Hamburg (Germany). The agenda includes lectures about anorexia and cachexia, environmental and hospital contamination with cytostatics drugs, treatment of elderly and personalized cancer medicine. Among a lot of eminent and respected lecturers will be also representatives of patientís oncology organizations.

As the last years a poster display is planed in order to giveall posterpresenter, the chance to congress program on Saturday participate for free. Please admit your poster abstract (max. 350 words) via e-mail to s.braband@conevent.de until December 31th 2010.

The program, registration form and poster presentation you can find online on www.nzw.de/nzw_europe.php.




The ESOP board has had a meeting in Brussels between October 25th and 27th 2010.

During 2 days of debate has made the following decisions:


To start programs and projects in the frame work of ESOP to support the intentions and to support the knowledge in ECCO of ESOP.
The most important topics of the next activities will be: extravasations, compliance and adherence, pharmacovigiliance, pharmacokinetics and pharmacodynamics in the elderly based on population methods, drug-drug interactions and clinical trial management in the elderly.
The 12th ESOP congress will change name to ECOP12, European Conference of Oncology Pharmacy and will be organized by ESOP/ECCO in Budapest on late September or early October in 2012. There will parallel sessions and poster sessions.
The Master Class should give the participants certification valuable throughout Europe and should be divided into Basic and Advanced Master Class. On the second day of meeting the ESOP Board had a discussion with the ECCO representatives, Michael Ballieu CEO and Adline Lewuillon Congress Operation Manager, about future collaboration. Moreover, ECCO by the European School of Oncology has shown an interest to support coming Master Class. ECCO is a federation with about 50.000 members from 24 organizations for scientific affairs in oncology covering all aspects of the disease. The ECCO mission is in Europe focusing on education, favorably multiprofessional and public affairs. The tag line is
"Every cancer patient deserves the best".




One day before the 7th Polish-German Conference of Oncology Pharmacy in Wroclaw (Poland), on September 23th was held the first meeting of the new structure in Poland – Polish Oncology Pharmacists Association (POPA). During this event was elected the POPA Board. Slawomir Waryszak had been chosen on POPA President, Bogumila Sobkowiak and Olga Fedorowicz – Vicepresidents, Dr Lukasz Lapinski – Secretary, Dr Jerzy Lazowski – Treasurer and Prof. Anna Wiela-Hojenska and Teresa Pociecha on members of POPA Board. Now POPA has almost 40 members. The next meeting is going to take place in Wroclaw between April 7th and 9th during the seminars about the treatment of cancer pain.




Clinical trials in oncology represent an important part of today's oncology pharmacists' job. QUAPOS 4 provides a reference guideline to be used to organize pharmacist activities related to clinical trials. However practices can differ from one country to another within Europe, considering different law regulations or historical involvement of pharmacists in this area. This study is dedicated to better clarify the actual involvement of oncology pharmacists in clinical trials management in Europe, and possibly identify actions to move forward. We would be grateful if you accept to fill this questionnaire until January 10th: results will be presented for next ECOP in January 2011.
Download